Wound-Healing Combo Product Jurisdiction Should Be Clarified – Ex-FDAer
This article was originally published in The Gray Sheet
Executive Summary
The regulatory pathway for wound-healing combination products should be elucidated because they increasingly are assigned to CBER and not the device center, according to The Biologics Consulting Group Senior Consultant Darin Weber, PhD